바이오사이토젠의 TCR 기술 플랫폼_Biocytogen Pharmaceuticals (Beijing) Co., Ltd._항체디스커버리, 항체의약품, 항체치료제, 항체신약, 항체약물, 이중항체, 이중특이성항체, 인간항체, 마우스플랫

Please input keywords

TCR항체플랫폼

Most traditional antibodies target cell surface antigens (PD-1 and PD-L1, etc) or soluble antigens. However, ideal tumor antigens are often intracellular, (RAS, P53, WT1, etc). Endogenous T cell receptor (TCR) can recognize intracellular antigen/HLA complex, i.e. MHC-antigen-peptide, MAP, to activate T cells against tumor cells. But their affinity to the antigen is low, which often leads to tumor immune escape.

Biocytogen's TCR-mimic (TCRm) antibody technology platform is designed for the discovery of TCRm antibodies with high affinity and specificity compared with endogenous TCRs.

Advantages of Biocytogen's TCR-mimic Antibody Platform

from clipboard

1. Biocytogen's unique HLA/RenMab mice combined with a high-throughput antibody screening platform enable a one-step process to obtain fully human antibodies that recognize MAP (MHC-antigen-peptide), with higher affinity and specificity than TCRs.

2. In situ complete human antibody variable gene replacement in RenMab and RenLite mice ensure the diversity of antibody sequences.

3. Beacon-based high-throughput antibody screening and sequence analysis accelerate the antibody discovery process.

4. Fully human antibody sequences obtained by our TCRm antibody technology platform provide more candidates for the development of antibody-based drugs such as bispecific antibodies, CAR-T, TCR-T, and other fields. By targeting intracellular antigens, TCRm antibodies can be developed into drugs that clear specific abnormal cells such as tumor cells, infected cells, and senescent cells. In addition, TCR-mimic antibodies can be screened by their blocking activity for the development of drugs blocking the autoimmune attack.

Biocytogen's Fully Human TCRm Antibody Discovery Workflow

from clipboard

TCR-mimic Antibodies under Development

from clipboard

Posters

AACR 2024: Targeting mutant KRAS proteins with novel TCR-mimic fully human antibodies

SITC 2023: Identification of fully human TCR-mimic antibodies targeting the KRAS G12V/HLA complex generated in HLA-transgenic RenMab mice

SITC 2023: Preclinical Application of a Fully Human TCR-mimic Antibody Developed to Target NY-ESO-1/HLA-A02

AACR 2023: Targeting Intracellular Tumor Antigens Using Fully Human TCR Mimic Antibodies Derived From HLA Transgenic RenMice

AACR 2022: Generation of TCR-mimic fully human antibodies against HLA-antigen-peptide complexes using HLA transgenic RenMice

PEGS EUROPE 2022: A Novel TCR-mimic Fully Human Antibodies Discovery Platform

Biocytogen and CtM Bio Achieve Milestone Progress in Co-Developing a TCR-mimic Antibody-based Multi-Specific T Cell Engager Targeting WT1/HLA-A02

Biocytogen Enters Agreement with CtM Bio to Co-Develop TCR-Mimic Antibody based Multi-Specific T cell Engagers

Biocytogen Announces Collaboration with FineImmune to Develop TCR-Mimic Antibody-based Cell Therapy

Prev:None

Next:이중특이성항체 플랫폼